Abstract Aim To evaluate the effectiveness, safety and cost-effectiveness of psychosocial interventions for cannabis use disorder (CUD). Methods A systematic review of randomized controlled trials (RCTs; PROSPERO protocol CRD42024553382) of psychosocial interventions for CUD lasting >4 sessions, delivered synchronously, to individuals with CUD aged ≥16 years, in inpatient, outpatient or community-based settings. We searched databases (MEDLINE/PsycInfo/Cochrane CENTRAL) to 12 June 2024. We assessed results using Risk of Bias 2 and conducted pairwise meta-analyses. Primary outcomes were continuous- and point-abstinence and withdrawal intensity at the end of treatment, treatment completion and adverse events. Results We included 22 RCTs (3304 participants). Relative to an inactive/non-specific comparator,...

Please use this link to access this publication. Introduction Concurrent use (co-use) of tobacco and cannabis is common among both adults and youth1. Co-use is linked to greater dependence and difficulty quitting both substances2, and increased toxicant exposure3. Overwhelmingly, co-use research has not established the most prevalent tobacco and cannabis product combinations involved. Improving understanding of this issue is important to guide emerging research involving smoking and vaping, since both substances are often consumed through these modalities. We examined prevalence of tobacco-cannabis co-use and the most common product combinations among US adults and youth. Methods Cross-sectional data were from Wave 7 (2022–2023) of the...

Please use this link to access this publication.  

Please use this link to access this publication.  

Please use this link to access this publication.

ABSTRACT Objective: Given the interest in the potential effects of cannabis on medical students, this study aims to establish the prevalence of recreational use within this population. Methods:We searched MEDLINE, LILACS, PubMed, Embase, PsycINFO/PsycArticles/APA Books), and SciELO for observational studies published before June 9, 2025, that reported cannabis use prevalence among medical students. We conducted subgroup analyses based on gender, study cycle, school type, decade of publication, and world region. Data were pooled using a random-effects model. Results: Our search identified 109 studies meeting the inclusion criteria, published between 1971 and 2025, encompassing data from 62,444 participants from 32 countries. Lifetime prevalence was 29.2%,...

Please use this link to access this publication.  

Background and objectives Patient access to medicinal cannabis (MC) is impacted by several factors, despite legalisation of it for medicinal and related scientific purposes in 2016. This scoping review aimed to examine the barriers and enablers to accessing MC through general practitioners (GPs) in Australia. Methods Scientific and grey literature meeting inclusion criteria were identified from 2016 to 2023, resulting in 11 papers and 40 webpages being included in this review. Results Many GPs reported inadequate knowledge surrounding MC, forming a barrier to their approachability to discussion with patients. Living rurally and earning less money were barriers to patients’ ability to seek MC. Telehealth cannabis...

Abstract A 63-year-old woman presented with intractable nausea, vomiting, dyspnea, and weakness after cannabis use. She had multiple prior admissions for cannabinoid hyperemesis syndrome. Upon arrival to the emergency department, she was hypotensive, tachycardic, and hypoxic. Laboratory results revealed an elevated troponin level (22,900 ng/L), NT-proBNP (21,092 pg/mL), lactic acidosis (lactic acid level of 7.1 mmol/L), and hypokalemia (potassium level of 2.6 mmol/L). The electrocardiogram showed ST-segment elevation in the anterior leads, and telemetry captured a wide complex tachycardia requiring cardioversion. The urine drug screening was positive for tetrahydrocannabinol. She was intubated and taken for urgent cardiac catheterization, which showed no coronary lesions. Right...